In this report, Amy Brown, Edwin Elmhirst and Joanne Fagg of Evaluate Vantage discuss the outlook for biopharma in 2023. According to the team, there is hope for an improvement in 2023 after the trials of the last two years, although few are expecting a dramatic recovery. Check out the Evaluate team’s thoughts on the […]
We were proud to host a fantastic panel chaired by BioCentury’s European Editor Stephen Hansen with Soren Moller, Managing Partner of Novo Seeds; Karin Kleinhans, Partner of MRL Ventures Fund; Hakan Goker, Managing Director of M Ventures; Roel Bulthuis, Managing Partner at Inkef. This panel of Venture Capital (VC) investors discussed the strength of private […]
6TH OCTOBER 2022 | LONDON
Novo Ventures senior partner, Naveed Siddiqi, discussed the opportunity in a slumbering IPO market to raise larger funding rounds, in an interview with Unquote.
Therese was selected as one of the top 30 Rising Leaders in the 3rd annual listing of In Vivo’s ‘Rising Leaders’ 2022.